Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation

Open access
Tie, Jeanne, Gibbs, Peter, Lipton, Lara, Christie, Michael, Jorissen, Robert N., Burgess, Antony W., Croxford, Matthew, Jones, Ian, Langland, Rachel, Kosmider, Suzanne, McKay, Daniel, Bollag, Gideon, Nolop, Keith, Sieber, Oliver M., Desai, Jayesh·2011·International Journal of Cancer

Abstract

BRAFV600E mutations are found in 10% of colorectal cancers (CRCs). The low frequency of this mutation therefore makes it a challenging target for drug development, unless subsets of patients with higher rates of BRAFV600E can be defined. Knowledge of the concordance between primary–metastasis pairs and the impact of BRAFV600E on outcome would also assist in optimal drug development. We selected primary CRCs from 525 patients (stages I–IV) evenly matched for age (<70 and ≥70), gender and tumor location (right, left and rectum), and 81 primary–metastasis pairs. BRAFV600E, KRAS mutation and microsatellite instability (MSI) were determined and correlated with clinical features and patient outcomes. In multivariate analyses, increasing patient age (p = 0.04), female gender (p = 0.0005) and right‐sided tumor location (p < 0.0001) were independently associated with BRAFV600E. The prevalence of BRAFV600E was considerably higher in older (age > 70) females with KRAS wild‐type right‐sided colon cancers (50%) compared to the unselected cohort (10%). BRAFV600E was associated with inferior overall survival in metastatic CRC (HR = 2.02; 95% CI 1.26–3.26), particularly evident in patients treated with chemotherapy, and is independent of MSI status. BRAF status was concordant in all primary tumors and matched metastases (79 wild‐type pairs and two mutant pairs). Clinicopathological and molecular features can identify CRC patients with a higher prevalence of BRAFV600E. Patients with BRAFV600E wild‐type primary tumor do not appear to acquire the mutation in their metastases, and BRAFV600E is associated with poorer outcomes in metastatic patients. Our findings are timely and will help inform the rational development of BRAFV600E inhibitors in CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.25555

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 227

Metadata

Authors
Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., McKay, D., Bollag, G., Nolop, K., Sieber, O. M., & Desai, J.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2011-03-08
Volume
128
Issue
9
Pages
2075-2084
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2072599380
Cited by
227
References
7
FWCI
4.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. https://app.cochat.ai/papers/10.1002/ijc.25555
The paper
Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., McKay, D., Bollag, G., Nolop, K., Sieber, O. M., & Desai, J. (2011). Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. International Journal of Cancer. https://doi.org/10.1002/ijc.25555

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.